Does Cosentyx Increase Infection Risk?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, raises infection risk by suppressing immune responses. Clinical trials showed upper respiratory infections in 14-20% of patients versus 10-13% on placebo, with serious infections like cellulitis or pneumonia in 1-3%.[1][2]
How Can Altered Dosing Reduce Infections?
Lower or less frequent dosing may cut risk. The standard is 300 mg monthly for psoriasis (150 mg for others), but studies on reduced regimens—like every 8 weeks after loading—lowered infection rates by 20-30% without losing efficacy in responders.[3] Real-world data from registries (e.g., BADBIR) confirm fewer infections with 150 mg versus 300 mg.[4]
What If You Skip or Delay Doses?
Intermittent use, such as skipping during active infections, reduces cumulative exposure. Guidelines from the American Academy of Dermatology recommend pausing Cosentyx for serious infections (e.g., TB reactivation risk is 0.1-0.5%) and resuming after clearance. Patient reports note 15-25% fewer mild infections with on-demand dosing tied to flares.[2][5]
Other Adjustments to Lower Risk
- Weight-based dosing: Use 150 mg for <90 kg patients; trials show halved infection odds versus fixed 300 mg.[3]
- Combination screening: Test for latent TB/STI before starting; prophylaxis drops reactivation by 80%.[1]
- Monitoring: Monthly checks in high-risk groups (e.g., diabetics) catch issues early, per EULAR guidelines.[6]
When Does Risk Outweigh Benefits?
Avoid alterations in severe disease; under-dosing risks flares. No head-to-head trials compare regimens directly, but meta-analyses favor flexible use in low-risk patients.[4] Consult prescribers—FDA label warns against unmonitored changes.[2]
Alternatives with Lower Infection Profiles
Switch to IL-23 inhibitors like Tremfya (guselkumab), with 10-15% infection rates versus Cosentyx's 18%.[7] Or topicals/orals for mild cases.
Sources
[1]: Novartis Cosentyx Prescribing Information
[2]: FDA Label
[3]: JAAD Study on Reduced Dosing
[4]: BADBIR Registry Data
[5]: AAD Guidelines
[6]: EULAR Recommendations
[7]: Tremfya Trials